Lightwave Logic

Refresh delta (since 2026-06-17)

1. Revenue is still negligible: $32,751 in Q2 2026 (Q2 2025: $25,605) and $61,918 for the six months (2025: $48,522), all licensing and royalty revenue under the May 2023 material supply and license agreement [10-QForm 10-QThe quarterly version of the annual report. Lighter, and not audited., results of operations and Note 3]. One customer was 10% or more of revenue in both periods, which is all of it [10-Q, concentration note]. The prior dossier's headline revenue was $237K for FY2025. The 10-Q says revenue recognized during 2026 would "primarily relate to material supply, NRE arrangements, or prototype and development activities" and that the company does not expect significant revenue from volume commercial production "until 2027 at the earliest" [10-Q, MD&A]. The prior dossier quoted the same "2027 at the earliest" language.

2. Losses and expenses rose. Q2 2026 net loss $6,613,797 (Q2 2025, restated: $4,966,633, +33%); six-month net loss $12,914,337 (2025: $9,663,657, +34%). Q2 research and development $3,878,703 (+48%) and general and administrative $3,423,188 (+49%) [10-Q, MD&A; Q2 2025 figures are restated, see fact 5]. Q1 2026 net loss was therefore $6.3M, which matches the figure the prior dossier recorded. The 10-Q attributes the increases to salary and benefits, non-cash stock compensation, professional and legal fees, and, for the half, prototype device development and wafer fabrication [10-Q, MD&A]. Interest income was $652,071 in Q2 [10-Q, statement of comprehensive loss].

3. Cash and runway. At 2026-06-30: cash and cash equivalents $47,209,148 and marketable securities $48,701,814, against cash $69,017,354 and no marketable securities at 2025-12-31 [10-Q balance sheet]; together $95.9M. Six-month operating cash use $9,882,537 (2025: $7,260,222); investing used $50,478,319 (of which $48,714,585 purchases of marketable securities and $1,518,336 property and equipment); financing provided $38,555,054 [10-Q, cash-flow statement]. At the first-half pace of operating cash use plus property, equipment and intangibles spending, about $1.9M a month, $95.9M is about 49 months, arithmetic on the first-half pace and not a forecast; the prior dossier's estimate was 30-36 months from $75.1M of cash at 2026-03-31. Management's statement is unchanged: cash, cash equivalents and marketable securities are sufficient "through at least December 2027" [10-Q, Note 3].

4. Funding and dilution in the half. Net proceeds in the six months: $27,883,978 from the Roth at-the-market facility, $4,930,928 from the January over-allotment exercise on the December 2025 Titan offering, $1,362,932 from exercise of the 402,500 underwriter warrants on 2026-04-14, and $6,946,686 from option exercises [10-Q, liquidity]. On 2026-04-20 the Roth facility was raised from $35.0M to $51,404,500, and the company has sold $51,401,115 under it, leaving $3,385 available [10-Q, Note 3]. The prior dossier called that facility "nearly exhausted"; it is now fully used. Shares outstanding were 154,166,422 at 2026-06-30 against 146,050,506 at 2025-12-31, up 5.6% in six months [10-Q balance sheet; estimate: 154,166,422 / 146,050,506 − 1]. Total assets $108.1M, total liabilities $3.9M [10-Q balance sheet]. The prior dossier says a new institutional facility appeared in 2026; the 10-Q names no new facility, and records that a 36-month purchase agreement with an institutional investor, signed 2025-03-17 for up to $30,000,000, was terminated on 2025-12-15 after $3,646,655 had been received [10-Q, Note 3].

5. Restated comparatives. The 10-Q labels 2025 comparative periods and the 2024 opening balance "restated", and Note 2 says the corrections concern the accounting for certain non-cash stock option exercises, derived from a Form 10-Q/A filed on 2026-01-20 that the note directs readers to for the quantitative impact [10-Q, Note 2]. That 10-Q/A was not read in this run. The prior dossier described a "benign FY2021 SBC restatement"; the 10-Q's Note 2 describes a different correction and does not mention 2021. Management concluded disclosure controls and procedures were effective at 2026-06-30 [10-Q, Item 4].

6. New CFO. On 2026-07-20 the board appointed Fred A. Graffam III, age 60, as Chief Financial Officer, effective immediately; he was CFO of Fidium (formerly Consolidated Communications) from December 2022 to April 2026 and earlier of Monitronics and Ascent Capital. Terms: base salary $450,000, discretionary bonus up to 40% of base, $70,000 sign-on cash, and sign-on restricted stock units with a grant-date value of $2,400,000 vesting 25% after one year and the rest quarterly over three years. Snizhana Quan, Principal Financial and Accounting Officer since January 2026, stays as Vice President of Finance and Corporate Controller [8-KForm 8-KA filing for something that happened between reports and matters enough to tell shareholders now. CFO, Item 5.02 and exhibit 99.1; 10-Q Note 17]. The prior dossier's Lens 14 question 10 asks about SOX readiness as commercialization scales.

7. New director. Edward H. Kennedy (Extreme Networks director since 2011; former CEO of CENX and of Tollgrade Communications) was appointed to the board effective 2026-09-23, expanding it to seven members [8-K board, Item 5.02 and exhibit 99.1].

8. Commercial model text in the 10-Q. The 10-Q says the company's strategy is materials supply, IP licensing, PDK enablement and royalty or other fee arrangements tied to customer production, and that licenses are non-exclusive and royalty-bearing; customers and prospects named by type are foundries, silicon photonics designers, optical module makers and system integrators. It describes a four-stage customer process (Stage 3 typically 12-18 months, Stage 4 production ramp) with the whole cycle about 18 to 24 months, and warns that advancement to later stages does not assure commercial production [10-Q, business and MD&A text]. The 10-Q passages read name no customer, foundry or Stage-3 count; those items in the prior dossier were web-sourced.

What held

• The prior dossier's runway claim ("into 2028", management "through at least December 2027") is unchanged in the filing, and the cash position is higher than at 2026-03-31 because of the half's raises (facts 3 and 4).
• The structural-dilution flag held: shares outstanding rose 5.6% in six months and the Roth facility is fully used (fact 4).
• Revenue timing: the 10-Q repeats that significant volume production revenue is not expected before 2027 at the earliest (fact 1). Revenue of $61,918 for the half is consistent with the prior dossier's "sub-$250K-revenue company" framing.
• Burn did re-accelerate, as the prior dossier's question 8 suggested: six-month net loss +34% and Q2 operating expenses +48% (fact 2).
• The position seed's catalysts (devices back from foundries in Q3-Q4 2026, additional Stage-3 customers by end-Q3 2026, a first Stage-4 win) are not settled by anything read here; no filing read reports any of them. The seed is carried unchanged below.